NASDAQ:FMI - Foundation Medicine Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $137.00 0.00 (0.00 %) (As of 09/21/2018 04:00 PM ET)Previous Close$137.00Today's Range$137.00 - $137.0052-Week Range$31.70 - $137.20VolumeN/AAverage Volume621,352 shsMarket Capitalization$5.09 billionP/E Ratio-30.44Dividend YieldN/ABeta-0.1 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. It also has a three-party collaboration agreement with F. Hoffmann-La Roche Ltd and DIAN Diagnostics Group, Co., Ltd. to integrate the company's comprehensive genomic profiling assays into clinical patient care in mainland China. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc. Receive FMI News and Ratings via Email Sign-up to receive the latest news and ratings for FMI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical SymbolNASDAQ:FMI CUSIPN/A Webwww.foundationmedicine.com Phone617-418-2200 Debt Debt-to-Equity Ratio4.76 Current Ratio2.27 Quick Ratio1.98 Price-To-Earnings Trailing P/E Ratio-30.44 Forward P/E Ratio-31.07 P/E GrowthN/A Sales & Book Value Annual Sales$152.90 million Price / Sales33.28 Cash FlowN/A Price / CashN/A Book Value$0.87 per share Price / Book157.47 Profitability EPS (Most Recent Fiscal Year)($4.50) Net Income$-161,460,000.00 Net Margins-84.96% Return on Equity-299.63% Return on Assets-94.81% Miscellaneous Employees662 Outstanding Shares37,140,000Market Cap$5.09 billion Foundation Medicine (NASDAQ:FMI) Frequently Asked Questions What is Foundation Medicine's stock symbol? Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI." How were Foundation Medicine's earnings last quarter? Foundation Medicine Inc (NASDAQ:FMI) announced its quarterly earnings results on Wednesday, May, 2nd. The company reported ($1.02) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.10) by $0.08. The business had revenue of $52.84 million for the quarter, compared to analyst estimates of $44.99 million. Foundation Medicine had a negative return on equity of 299.63% and a negative net margin of 84.96%. The company's quarterly revenue was up 100.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.31) EPS. View Foundation Medicine's Earnings History. What price target have analysts set for FMI? 4 Wall Street analysts have issued 12 month target prices for Foundation Medicine's stock. Their predictions range from $73.00 to $90.00. On average, they expect Foundation Medicine's share price to reach $81.00 in the next twelve months. This suggests that the stock has a possible downside of 40.9%. View Analyst Price Targets for Foundation Medicine. What is the consensus analysts' recommendation for Foundation Medicine? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foundation Medicine in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Foundation Medicine. Who are some of Foundation Medicine's key competitors? Some companies that are related to Foundation Medicine include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), Natera (NTRA), InVitae (NVTA), CareDx (CDNA), RadNet (RDNT), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD) and Fulgent Genetics (FLGT). Who are Foundation Medicine's key executives? Foundation Medicine's management team includes the folowing people: Mr. Troy Cox, CEO, Pres & Director (Age 54)Mr. Michael Doherty, Head of Product Devel. (Age 59)Mr. Jason Ryan, Chief Financial Officer (Age 44)Mr. Konstantin Fiedler, Chief Operating Officer (Age 52)Mr. Tom Godden, Chief Information Officer Has Foundation Medicine been receiving favorable news coverage? News stories about FMI stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foundation Medicine earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media coverage about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Foundation Medicine. Who are Foundation Medicine's major shareholders? Foundation Medicine's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.95%), Gilder Gagnon Howe & Co. LLC (3.60%), Chevy Chase Trust Holdings Inc. (2.19%), Casdin Capital LLC (1.84%), Baillie Gifford & Co. (1.09%) and Morgan Stanley (1.03%). Company insiders that own Foundation Medicine stock include David Daly, Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Krishna Yeshwant, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Roche Holdings Inc, Steven J Kafka, Troy Cox and Vincent A Miller. View Institutional Ownership Trends for Foundation Medicine. Which institutional investors are selling Foundation Medicine stock? FMI stock was sold by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc., Boston Advisors LLC, Chevy Chase Trust Holdings Inc., ARK Investment Management LLC, Gilder Gagnon Howe & Co. LLC, Prentiss Smith & Co. Inc., Peregrine Capital Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Foundation Medicine company stock in the last year include Evan/ Fa Jones, Jason Ryan, Konstantin Fiedler, Michael J Doherty, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Insider Buying and Selling for Foundation Medicine. Which institutional investors are buying Foundation Medicine stock? FMI stock was bought by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Morgan Stanley, Water Island Capital LLC, Gamco Investors INC. ET AL, Bank of America Corp DE, Casdin Capital LLC, Chicago Capital Management LLC and GABELLI & Co INVESTMENT ADVISERS INC.. View Insider Buying and Selling for Foundation Medicine. How do I buy shares of Foundation Medicine? Shares of FMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Foundation Medicine's stock price today? One share of FMI stock can currently be purchased for approximately $137.00. How big of a company is Foundation Medicine? Foundation Medicine has a market capitalization of $5.09 billion and generates $152.90 million in revenue each year. The company earns $-161,460,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Foundation Medicine employs 662 workers across the globe. How can I contact Foundation Medicine? Foundation Medicine's mailing address is 150 Second Street, Cambridge MA, 02141. The company can be reached via phone at 617-418-2200 or via email at [email protected] MarketBeat Community Rating for Foundation Medicine (NASDAQ FMI)Community Ranking: 1.7 out of 5 ()Outperform Votes: 170 (Vote Outperform)Underperform Votes: 332 (Vote Underperform)Total Votes: 502MarketBeat's community ratings are surveys of what our community members think about Foundation Medicine and other stocks. Vote "Outperform" if you believe FMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FMI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/22/2018 by MarketBeat.com StaffFeatured Article: What is the Ex-Dividend Date in Investing?